Linklaters advises banks on financing for the acquisition of SpringWorks Thera-peutics by Merck KGaA

Linklaters has advised the mandated lead arrangers on the bridge financing in connection with the acquisition of SpringWork Therapeutics by Merck KGaA. Linklaters is supporting the financing banks in all legal aspects of the financing.

 SpringWorks Therapeutics is a U.S. biopharmaceutical company developing innovative therapies for rare tumor diseases. The acquisition of SpringWorks strengthens Merck Healthcare's presence in the U.S. and expands access to innovative therapies for rare tumors worldwide.

The Linklaters team advised under the leadership of Marc Trinkaus (Partner, German Head of Banking) and Dr Urs Lewens (Counsel, Banking, both Frankfurt). Other team members were Pierre-Emmanuel Perais (Partner, Corporate/M&A, New York), Dr Ulrich Johann (Counsel, Tax, Frankfurt) and Dr Lasse Petersen Weis (Managing Associate, Banking, Frankfurt). The associates in the team included Arthur Weilert (Tax), Martin Reschke (Banking), Dr Philipp Bergjans (Banking, all Frankfurt), Lu Meng (Corporate/M&A, New York) and Michal Folczyk (Law Clerk, Banking, New York).